RT Journal Article
SR Electronic
T1 Aerosol measurement identifies SARS-CoV 2 PCR positive adults compared with healthy controls
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.21.22269423
DO 10.1101/2022.01.21.22269423
A1 Gutmann, Desireé
A1 Scheuch, Gerhard
A1 Lehmkühler, Timon
A1 Herrlich, Laura-Sabine
A1 Hutter, Martin
A1 Stephan, Christoph
A1 Vehreschild, Maria
A1 Khodamoradi, Yascha
A1 Gossmann, Ann-Kathrin
A1 King, Florian
A1 Weis, Frederik
A1 Weiss, Maximilian
A1 Rabenau, Holger F
A1 Graf, Juergen
A1 Donath, Helena
A1 Schubert, Ralf
A1 Zielen, Stefan
YR 2022
UL http://medrxiv.org/content/early/2022/01/21/2022.01.21.22269423.abstract
AB Background SARS-CoV-2 is spread primarily through droplets and aerosols. Exhaled aerosols are generated in the lung periphery by ‘reopening of collapsed airways’. Aerosol measuring may detect highly contagious individuals (“super spreaders or super-emitters”) and discriminate between SARS-CoV-2 infected and non-infected individuals. This is the first study comparing exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls.Design A prospective observational cohort study in 288 adults, comprising 64 patients testing positive by SARS CoV-2 PCR before enrollment, and 224 healthy adults testing negative (matched control sample) at the University Hospital Frankfurt, Germany, from February to June 2021. Study objective was to evaluate the concentration of exhaled aerosols during physiologic breathing in SARS-CoV-2 PCR-positive and -negative subjects. Secondary outcome measures included correlation of aerosol concentration to SARS-CoV-2 PCR results, change in aerosol concentration due to confounders, and correlation between clinical symptoms and aerosol.Results There was a highly significant difference in respiratory aerosol concentrations between SARS-CoV-2 PCR-positive (median 1490.5/L) and -negative subjects (median 252.0/L; p<0.0001). There were no significant differences due to age, sex, smoking status, or body mass index. ROC analysis showed an AUC of 0.8918.Conclusions Measurements of respiratory aerosols were significantly elevated in SARS-CoV-2 positive individuals and may become a helpful tool in detecting highly infectious individuals via a noninvasive breath test.Clinical Trial Number ClinicalTrials.gov Identifier: NCT04739020.Summary of the main point In this prospective, comparative cohort study, higher numbers of exhaled respiratory aerosols correlate with a positive PCR test for SARS-CoV-2. Measurement of exhaled aerosols may become a helpful tool in detecting contagious individuals via a readily available breath test.Competing Interest StatementCS declares receipt of grants or contracts from Gilead Sciences, Janssen, Merck/MSD, Roche, Shionogi, and ViiV Healthcare, and acted as a consultant for Astellas Pharma, Gilead Sciences, Janssen, Merck/MSD, and ViiV Healthcare. He has received support for attending meetings and/or travel from Gilead Sciences, Janssen, and ViiV Healthcare. YK has received honoraria for presentations from Merck/MSD and Gilead Sciences, and support for attending meetings and/or travel from Gilead Sciences and ViiV Healthcare. SZ declares receipt of grants or contracts from Bohringer Ingelheim (Germany), EU: Horizon 2020 Erydel in Ataxia, and DLR Projekttrager 01KG2030 (Tipp Study). He has received honoraria for presentations from Novartis GmbH, GSK, Vifor Pharma, Bohringer Ingelheim, Lofarma GmbH, Allergopharma GmbH, Allergy Therapeutics, and Sanofi Genzyme. SZ reports personal fees from Aimmune, Novartis GmbH, Bohringer Ingelheim, and IMS HEALTH GmbH & Co. OHG. FW and MW are employees of Palas GmbH and have other no disclosures or conflicts of interest. GS is Chief Executive Officer of GS BIO-INHALATION GmbH and has other no disclosures or conflicts of interest. DG, HD, FK, AG, HFR, JG, RS, and TL have no disclosures or conflicts of interest.Clinical TrialClinicalTrials.gov Identifier: NCT04739020Funding StatementThis work was supported by Palas GmbH, Partikel- und Lasermesstechnik, which provided aerosol measurement devices, as well necessary equipment, and limited sponsorship for conduction of the study. Additional resources were provided by the University Hospital Frankfurt, Goethe University. Palas GmbH reviewed the study data and final manuscript before submission, but the authors retained editorial control. Palas GmbH also provided funding for a medical writer to assist in manuscript preparation. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Goethe University Frankfurt (number 20-1001) and registered under the number ClinicalTrials.gov Identifier: NCT04739020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized participant data will be made available upon requests directed to the corresponding author. Proposals will be reviewed and approved by investigator and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. All data will be made available for a minimum of five years from the end of the trial.